Press release
Regulated information
6 April 2018, 5.45 p.m. CET

MDxHealth Shareholder Transparency Declaration

HERSTAL, BELGIUM and IRVINE, CA – April 6, 2018 – MDxHealth SA (Euronext Brussels: MDXH) (“MDxHealth” or the “Company”), a world leader in molecular diagnostics for urological cancers, announced that it received on April 4, 2018 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the “Belgian Transparency Act”).

Shareholdings after actively crossing the transparency threshold:

The Company was informed by the following shareholders that they still hold shares and voting rights in excess of 10% of the outstanding shares and voting rights of the Company:

For further information, reference is made to the information published on MDxHealth’s website (

About MDxHealth®
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of urological cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit and follow us on social media at: 

For more information: 
Jean-Marc Roelandt CFO                              Amber Fennell, Chris Welsh, Nicholas Brown
MDxHealth                                                      Consilium Strategic Communications
US: +1 949 812 6979                                      UK: +44 20 3709 5700
BE: +32 4 257 70 21                                

LifeSpring Life Sciences Communication
Leon Melens
NL: +31 6 538 16 427

Important information
The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA (the “Company” or “MDxHealth”). All other trademarks and service marks are the property of their respective owners.